ScreenerHero

DRTS Alpha Tau Medical Ltd.

NAS · US · Healthcare · Biotechnology · alphatau.com
14.25USD-1.59%Mkt Cap: 1.32B $P/E: —

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid ca…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.32B USD
Enterprise Value1.25B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-42.63M USD
Revenue/Share—
Last Price14.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-27.09
PEG—
EV/EBITDA-25.67
EV/Revenue—
P/S—
P/B30.36
EPS (TTM)-1.04
EPS (Forward)-0.53
52W Range
3.43089% of range15.63
52W High15.63 USD
52W Low3.430 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.29%
ROA-40.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.68M USD
CapEx (TTM)6.08M USD
FCF Margin—
FCF Yield-1.54%
Net Debt-85.49M USD
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.18
Current Ratio11.09
Quick Ratio10.45
Book Value/Sh0.48 USD
Cash/Share1.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)17.80 USD
Upside (mean)+24.9%
Target Range8.000 USD – 30.00 USD
8.000+24.9% to mean30.00
# Analysts5
Ownership
Shares Out.92.48M
Float64.10M
Insiders30.50%
Institutions9.22%
Short Interest
Short Ratio5.7d
Short % Float5.42%
Short % Out.3.77%
Shares Short3.48M
Short (prev mo.)3.06M
Technical
SMA 5014.17 (+0.6%)
SMA 2009.853 (+44.6%)
Beta1.22
S&P 52W Chg16.45%
Avg Vol (30d)473.33K
Avg Vol (10d)429.94K
Technical Indicators
RSI (14)46.7
MACD0.1362
MACD Signal0.2587
MACD Hist.-0.1225
BB Upper15.47 USD
BB Middle14.78 USD
BB Lower14.08 USD
BB Width9.41%
ATR (14)0.5999 USD
Vol Ratio (20d)0.97x